Human Genome Project: Write

On May 10th, a group of scientists led by George Church met in a closed-door, invitation only session to discuss the possibility of synthesizing the human genome. The intent was to publish a proposal outlining the need for human genome synthesis. That perspective piece was recently published in Science, and now has its own website. Among the goals and applications for human genome synthesis are:

 

  • To drive demand for large-scale DNA synthesis, and thus lower costs
  • To understand basic biology by re-creating noncoding DNA regions
  • To construct specific genotypes to study disease
  • To construct artificial chromosomes with all-included developmental pathways (minimal human cells, anyone?)
  • For gene therapy applications: improve safety by removing viral and cancer susceptibility, etc.
  • To recoding human cells for safety and biocontainment in manufacturing
  • To create a homozygous “pan-human” reference genome for drug testing

Drew Endy was invited but chose not to attend, instead exposing the meeting to the public and co-authoring an opinion piece on the ethics of human genome synthesis with our own Laurie Zoloth. Concerns raised in their piece include:

  • The secrecy and lack of public dialog severely damage public trust
  • The individuals involved have a financial conflict of interest
  • A non-human model organism genome synthesis project can provide the same demand to fuel low-cost DNA synthesis
  • No ethical analysis has been undertaken
  • A large potential for unintended consequences, especially on funding for the entire field of synthetic biology

What do you think? Join the discussion below!

Gene Drives

newgenedrive

On January 11th we learned about gene drives and explored their safety and regulation. This brought up key questions:

  • Can we really know enough about our environment to make gene drives safe?
  • Are there any issues with the currently advertised safety measures for gene drives?
  • What would be the ideal characteristics of a gene drive regulatory strategy?
  • How can gene drives be implemented responsibly?
  • What regulatory body would be qualified to make a decision about the use of a gene drive?

What do you think? Please join the discussion in the comments below.